ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Losing Stock Guy: Why He Went Wrong
By Kevin Matras

Quote:

Search for Ticker

Free Membership

Search:

CADX: Cadence Pharmaceuticals Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

CADENCE PHARMACEUTICALS INC (NASD)
CADX	8.61	N/A	(N/A%)	Vol. 0	N/A ET

Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III products in development, including IV APAP, for the treatment of acute pain and fever, and Omigard for the prevention of catheter-related infections. The Company is committed to the fevelopment and commercialization of pharmaceuticals to meet the needs of hospitalized patients and their caregivers.

General Information

CADENCE PHARMA

12481 High bluff drive Suite 200 San diege, CA 92130 Phone: 858 436 1400 Fax: 858-436-1401 Web: www.cadencepharm.com Email: None

Industry	MED-DRUGS
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	03/11/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	8.61
52 Week High	12.68
52 Week Low	4.39
Beta	1.19
20 Day Moving Average	500,267.81
Target Price Consensus	13.6

% Price Change
4 Week	-14.03
12 Week	-19.74
YTD	20.33

% Price Change Relative to S&P 500
4 Week	-14.96
12 Week	-24.33
YTD	-0.41

Share Information
Shares Outstanding (millions)	50.43
Market Capitalization (millions)	438.71
Short Ratio	24.15
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.35
Current Year EPS Consensus Estimate	-0.99
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	03/11/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.86
30 Days Ago	1.57
60 Days Ago	1.86
90 Days Ago	1.86

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	36.11%
vs. Previous Quarter	-35.29%

Sales Growth
vs. Previous Year	-%
vs. Previous Quarter:	-%

Price Ratios
Price/Book	4.95
Price/Cash Flow	-
Price / Sales	-

ROE
09/30/09	-55.97
06/30/09	-69.89
03/31/09	-97.82

ROA
09/30/09	-44.04
06/30/09	-50.83
03/31/09	-63.47

Current Ratio
09/30/09	6.66
06/30/09	7.91
03/31/09	7.35

Quick Ratio
09/30/09	6.66
06/30/09	7.91
03/31/09	7.35

Operating Margin
09/30/09	-
06/30/09	-
03/31/09	-

Net Margin
09/30/09	-
06/30/09	-
03/31/09	-

Pre-Tax Margin
09/30/09	-
06/30/09	-
03/31/09	-

Book Value
09/30/09	1.76
06/30/09	1.93
03/31/09	2.06

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	-

Debt-to-Equity
09/30/09	0.02
06/30/09	0.03
03/31/09	0.04

Debt to Capital
09/30/09	1.83
06/30/09	3.16
03/31/09	4.29


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research